ACINO HOLDING AG NEWS RELEASE - PRESSEMITTEILUNG
Acino appoints Dr. Barthold Piening as Chief Operations Officer and a Member of Group Management Aesch, July 4, 2014, 07.00 hrs - Acino announced today the appointment of
Dr. Barthold Piening as Chief Operations Officer and a Member of Group Management effective August 18, 2014. In this function he will be responsible for manufacturing, quality control, supply chain management, sourcing, safety and environmental protection at all sites of the Group. He will succeed Dr. Jürgen Betzing who has been in charge of global operations of the Acino Group (and previously Mepha) and has decided to leave the company to pursue other interests.
Jostein Davidsen, Acino's CEO, commented: "On behalf of Acino's Board and Management Team, I thank Jürgen Betzing for his strong commitment and dedication to our company. His valuable contributions were critical to the evolution of our manufacturing competencies, in obtaining FDA approval for our sites in Aesch and Miesbach, and during the integration of the operations acquired from Mepha. In the name of the leadership team and all Acino employees, we wish him all the best for the future. In welcoming Dr. Barthold Piening, he added: "In addition to his broad global operational and strategic experience in the pharmaceutical industry, Barthold Piening has a proven track record in successfully managing ambitious performance improvement projects while at the same time establishing a culture of operational excellence and quality awareness. We wish him much success in his new responsibilities."
Dr. Barthold Piening joins the Acino Group from Takeda Pharmaceuticals International GmbH, where he held the position of Head of Global Operations, overseeing 21 manufacturing sites with 5 000 employees worldwide. He graduated from the Kiel University with a PhD in Pharmaceutical Chemistry and holds an MBA from WHU Koblenz and Northwestern University of Chicago (Kellogg).
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Aesch BL.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista
Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding
AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the
Acino shares from the stock exchange.
Acino Holding AG
Dornacherstrasse 114
CH-4147 Aesch
Phone +41 61 338 60 00
Fax +41 61 338 60 80 www.acino-pharma.com
ContactRobert Schmid
Media & Investor Relations
Phone +41 61 338 61 15 robert.schmid@acino-pharma.com
Acino Holding AG
Page 2 / 2
Dornacherstrasse 114
CH-4147 Aesch
Telefon +41 61 338 60 00
Fax +41 61 338 60 80 www.acino-pharma.com
|
distributed by
|
